Gilead's Truvada May Cut HIV Infection Risk, FDA Says

Law360, New York (May 8, 2012, 7:56 PM EDT) -- Gilead Sciences Inc.'s Truvada, an antiretroviral drug widely used in HIV treatment, is effective at preventing HIV infection in at-risk individuals, according to a U.S. Food and Drug Administration report released Tuesday.

In two separate trials, Truvada's combination of tenofovir and emtricitabine taken as a pre-exposure prophylaxis greatly decreased rates of infection in individuals with HIV-infected sexual partners, according to the report.

The FDA's Antiviral Drugs Advisory Committee on Friday will consider Gilead's request to sell Truvada as a preventive treatment, which has been granted priority...
To view the full article, register now.